Ann: Appendix 3Y - Dr Daniel Tillett, page-33

Since Daniel has been involved, the management, ethics and ability of the board have been first class. They know the drug and its capabilities better than anyone else on the planet. As Daniel has stated on more than one occasion “we will do everything in our power to maximize shareholder returns.”
I understand that there are plenty of investors that are getting fatigue waiting, one of the holdups is the discovery of cardioprotection (this adds another $5 billion or more to the value.)
Having Daniel buy more shares isn’t a sign that he will let it go cheap, it’s a sign that he will have more control over the eventual sale price and won’t let it go for less than he believes it’s worth.